Zinzino Reports 21% Revenue Growth in April 2026, Driven by Strong Regional Performance
Event summary
- Zinzino Group revenue increased by 21% year-over-year to SEK 305.4 million in April 2026.
- Zinzino's sales markets saw a 22% revenue increase to SEK 300.8 million, while Faun Pharma's external sales decreased by 25% to SEK 4.6 million.
- Year-to-date revenue for January-April 2026 increased by 26% to SEK 1,227.5 million.
- North America and South America showed significant growth with 36% and 471% increases respectively.
- Central Europe and East Europe exhibited contrasting trends, with Central Europe growing by 37% and East Europe declining by 4%.
The big picture
Zinzino's 21% revenue growth in April 2026 highlights its strong market positioning, particularly in North America and Central Europe. The contrasting performance between Zinzino's sales markets and Faun Pharma suggests potential strategic realignment. The company's ability to maintain this momentum will be critical in a competitive healthcare and pharmaceutical landscape.
What we're watching
- Regional Performance
- How Zinzino will sustain growth in high-performing regions like North America and South America while addressing declines in East Europe.
- Faun Pharma Decline
- Whether the 25% drop in Faun Pharma's external sales indicates broader challenges or temporary setbacks.
- Market Strategy
- The pace at which Zinzino can leverage its strong regional performance to drive overall group revenue growth.
Related topics